Harmony Biosciences Holdings Inc Ordinary Shares HRMY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting
-
Harmony Biosciences to Participate in Upcoming Investor Conferences
-
Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities
-
Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026
-
Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting
-
Harmony Biosciences Appoints Glenn Reicin as Chief Financial Officer
-
Harmony Biosciences Gets FDA Approval for Cataplexy Treatment for Children With Narcolepsy
-
11 fast-growing small-cap stocks that could get a boost from the Fed's next move
Trading Information
- Previous Close Price
- $38.21
- Day Range
- $36.17–38.50
- 52-Week Range
- $25.52–40.87
- Bid/Ask
- $34.00 / $39.00
- Shares Outstanding
- 57.89M
- Market Cap
- $2.13B
- Volume/Avg
- 668,823 / 839,020
Key Statistics
- Price/Earnings (Normalized)
- 12.26
- Price/Sales
- 2.49
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 293
Valuation
|
Metric
|
HRMY
|
|---|---|
Price/Earnings (Normalized) | 12.26 |
Price/Book Value | 2.43 |
Price/Sales | 2.49 |
Price/Cash Flow | 8.19 |
Price/Earnings
HRMY
Financial Strength
|
Metric
|
HRMY
|
|---|---|
Quick Ratio | 3.45 |
Current Ratio | 3.58 |
Interest Coverage | 13.45 |
Quick Ratio
HRMY
Profitability
|
Metric
|
HRMY
|
|---|---|
Return on Assets (Normalized) | 14.99% |
Return on Equity (Normalized) | 21.58% |
Return on Invested Capital (Normalized) | 17.28% |
Return on Assets
HRMY
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|NLQ?nz | LOCK|<G>k^ | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|sw$VJCZ | LOCK|pz&DV | $70B | |||
| argenx SE ADR
ARGX
| LOCK|&>c^%R@ | LOCK|rM> | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|kcM%xR | LOCK|XNyk | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|&?hs@d@ | LOCK|M!? | $36B | |||
| Moderna Inc
MRNA
| LOCK|Z$zpJG | LOCK|h@ | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|@BKgT>r | LOCK|#pbj^ | $25B | |||
| Incyte Corp
INCY
| LOCK|h$%Cc& | LOCK|c$ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|YTV@<> | LOCK|h< | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|?lTZZ^? | LOCK|MbF | $17B |
United States